In tablet compression of HEMAFER ferric hydroxide polymaltose complex, high-dose oral solids are formulated with a target labelled elemental iron content of 100 mg per unit. The API quantity is determined from lot-specific elemental iron assay, commonly corresponding to 312.5 mg to 400 mg of complex per tablet when the certificate of analysis declares elemental iron in the 25% to 32% w/w range. Direct compression is constrained by the dense, dark-brown powder characteristics of the complex; the material exhibits poor flow with a Carr index frequently above 25% and high bulk density, which creates weight variation and segregation risks in high-speed rotary presses. Roller compaction is therefore applied at a roll pressure between 4 MPa and 8 MPa using a compactor with 25 mm to 40 mm roll diameter and side seal pressure adjusted to reduce leakage; the resulting ribbons are milled through a 1.0 mm screen and classified to retain a 16–80 mesh fraction. Dry granulation avoids the dark leachability of the iron complex into aqueous granulation fluids, but requires pre-conditioning at 25°C ± 2°C and relative humidity below 40% for at least 4 h when storage has exceeded 60% RH.

The dry granulate is blended with microcrystalline cellulose PH102 at 15% to 30% w/w, crospovidone at 2% to 5% w/w as disintegrant, and magnesium stearate at 0.5% to 1.0% w/w added in the final 3 min of blending at 12 rpm in a bin blender. Tablet compression on a rotary press is maintained at 15 kN to 25 kN for 19 mm × 9 mm oval tooling, producing a tablet hardness of 80 N to 120 N and friability not more than 1.0% by Ph. Eur. 2.9.7. Disintegration is measured in 900 mL of 0.1 N HCl at 37°C ± 0.5°C using Ph. Eur. 2.9.1; residual cores must dissipate within 30 min. Dissolution testing by USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N HCl uses atomic absorption or ICP-OES quantification of iron release; a typical immediate-release criterion is not less than 75% labelled iron at 45 min. Uniformity of dosage units is verified according to USP <905> / Ph. Eur. 2.9.40 with acceptance value not greater than 15.0. Film coating with a polyvinyl alcohol-based ready-mix at 2% to 3% w/w weight gain is performed on a side-vented pan at an inlet air temperature of 60°C to 70°C and a bed temperature of 38°C to 42°C; the coating step must not raise tablet moisture above 2.5% w/w by Karl Fischer titration.

Cleaning validation after tablet compression is non-trivial because the dark iron complex adheres to punch faces, die bores, and dust extraction ducts. Swab sampling is performed with 1% v/v nitric acid, and residual iron is quantified by ICP-MS; acceptance limits are derived from a maximum allowable carryover of 10 mg/kg of the next product and a swab recovery factor determined over 80% to 120%. Punch tip lubrication and dry dust extraction are preferred over external lubricant sprays because oil-based lubricants reduce tablet hardness and increase disintegration time. A production-scale issue is film-coating edge wear: the high density of the iron complex increases tablet weight and can generate rim chipping during pan loading; pan speed is limited to 2 rpm to 6 rpm and baffle depth is reduced to lower drop impact. The finished tablet is stored in cold-form aluminium blisters at 25°C ± 2°C and 60% ± 5% RH for long-term stability; accelerated conditions of 40°C ± 2°C and 75% ± 5% RH are used for 6 months to support a tentative shelf-life under ICH Q1A(R2).

What Limits Taste Masking and Saliva-Activated Disintegration in Pediatric Chewable Iron Polymaltose Tablets?

Pediatric and maternal chewable dosage forms are formulated with ferric hydroxide polymaltose complex at 25 mg to 50 mg elemental iron per unit to permit weight-based splitting while avoiding the metallic aftertaste associated with ferrous salts. The formulation shifts from compactable fillers to sweet-tasting, water-soluble polyols; mannitol or xylitol is used at 40% to 60% w/w, and sucralose at 0.05% to 0.15% w/w together with a bitter-masking flavour is pre-blended for 8 min at 15 rpm. Because the complex is practically insoluble in water and only slowly ionises in saliva, the taste challenge is primarily particulate grittiness and dark colour rather than ionic astringency. A high-shear wet granulation step is avoided; instead, dry granulation followed by direct compression keeps the granule porosity high enough to break down under chewing. Tablet hardness is held at 40 N to 70 N on 12 mm round tooling, with friability below 1.0% by Ph. Eur. 2.9.7. A disintegrant combination of crospovidone 2% to 3% w/w and mannitol 40% to 60% w/w gives saliva-activated disintegration below 60 s in 10 mL synthetic saliva medium at 37°C when tested by the rotating Petri dish method; however, a formal pharmacopoeial method for chewable disintegration is not harmonised, so product-specific breakability and texture are controlled by sensory panel and hardness profiles. Moisture uptake is the critical process conflict: the polyol matrix can absorb atmospheric water above 50% RH, softening tablets and reducing disintegration time; therefore, compression rooms are maintained at 20°C to 25°C and 30% to 40% RH, and tablets are packaged in aluminium–aluminium blisters with desiccant. Uncoated chewable tablets are not film-coated; colour contrast from the dark complex is managed by opaque packaging and a uniform blend colour achieved by geometric dilution of the API with mannitol prior to final blending.

Process control in chewable compression focuses on avoiding punch filming and lamination caused by the polyol matrix and the iron complex. The API is pre-mixed with colloidal silicon dioxide at 0.5% to 1.0% w/w before addition to mannitol to reduce cohesive adhesion to tooling. Compression speed is set at 30 rpm to 60 rpm, and lower punch dwell is increased by using flat-faced bevel-edge tooling rather than concave punches to maintain hardness without elevating compression force above 8 kN. The final dosage form is not coated, so cleaning of the tablet press and dedusting equipment must remove residual iron-polymaltose dust from contact surfaces; a visible residue limit is supplemented by swab analysis because the dark colour masks low-level contamination to the human eye. Stability data for chewable tablets are generated under 25°C ± 2°C and 60% ± 5% RH and under 30°C ± 2°C and 65% ± 5% RH; moisture-induced softening is monitored by hardness, disintegration, and related substance testing. A 50 mg elemental iron chewable tablet should disperse in 10 mL of water within 60 s under gentle stirring to support flexible administration.

Granule Fill Uniformity and Capsule Shell Moisture Transfer

To deliver 100 mg elemental iron in a hard capsule, the iron polymaltose complex must be granulated to a free-flowing, dense fill without exceeding the fill weight limits of size 0 or size 00 capsules. The granulate is produced by roller compaction at 4 MPa to 6 MPa; the milled fraction is classified to 20–40 mesh with fines below 100 µm not more than 10% w/w to prevent tamping pin segregation on automatic capsule fillers. Fill weight is set at 450 mg to 800 mg depending on capsule size, with target mass variation at ±3% on production-scale machines; uniformity of dosage units is confirmed by USP <905> acceptance value not greater than 15.0. The capsule fill must contain sodium starch glycolate 2% to 4% w/w as an intragranular disintegrant and magnesium stearate 0.5% to 0.75% w/w as lubricant, blended for 3 min at 12 rpm to avoid excessive lubricant coating of granule pores. Dissolution is performed per USP <711> Apparatus I at 100 rpm in 900 mL of 0.1 N HCl; the capsule shell must disintegrate within 5 min, and the label claim release criterion is not less than 75% at 45 min. Hard gelatin capsules absorb moisture from the environment and can embrittle below 35% RH, while HPMC capsules experience higher moisture permeability; in both cases, the equilibrium capsule shell moisture is maintained at 13% to 16% w/w for gelatin and 3% to 7% w/w for HPMC, respectively, by packaging in PVC/PVDC or cold-form aluminium blisters. Iron complex granules are hygroscopic only to a limited extent, but the granulate moisture is controlled below 3.0% w/w by Karl Fischer before filling to avoid dissolution slowdown and capsule wall staining.

Filling line observations show that capsule fill weight drift is primarily caused by granule density changes after transfer from the roller compactor to the tamping pin hopper. The granulate is therefore equilibrated in a bin at 20°C to 25°C and 30% to 40% RH for 12 h before filling, and the hopper is fitted with an agitator rotating at 10 rpm to 15 rpm to prevent bridging at the feed shoe. A capsule sorter and metal detector are installed after filling; ferric hydroxide polymaltose complex itself is not metallic, but wear particles from stainless steel contacts may be detected. Dissolution testing after storage is critical because capsule shell cross-linking in gelatin capsules can occur under high temperature and trace aldehyde exposure; HPMC shells are preferred where stability stress testing shows pellicular dissolution lag times above 5 min. The capsule product is not intended for opening or sprinkling; however, the granules may be transferred to soft food if the shell is removed, provided dissolution of the granules alone is verified in 0.1 N HCl by USP <711> with the same acceptance criterion.

For single-dose sachet granules containing elemental iron equivalent to 100 mg per 1 g sachet, fluidised-bed granulation is used to attach the iron polymaltose complex to a mannitol or sucrose ester substrate with a povidone K30 binder solution at 5% w/w in purified water. The inlet air temperature is set between 60°C and 70°C, product temperature is kept at 30°C to 35°C, and spray rate is adjusted to 20 g/min to 40 g/min per kg of dry substrate; atomising air pressure is maintained at 1.5 bar to 2.5 bar to avoid uncontrolled local wetting and dark granule agglomeration. The granulate is dried to a loss on drying of 1.0% to 2.5% w/w and sieved through a 500 µm screen; a particle size distribution with not less than 80% w/w retained between 150 µm and 500 µm and fines below 75 µm not more than 5% w/w is needed to reduce dusting and electrostatic adhesion to sachet laminate. Sachets of 1.0 g ±5% are filled on vertical form-fill-seal equipment from aluminium-laminate film; seal integrity is verified to ASTM F88/F88M with a seal strength of not less than 1.5 N/15 mm at 300 mm/min separation speed. Residual oxygen in the sealed sachet headspace is controlled below 5% v/v and moisture is protected by an integrated desiccant or by a cold-form laminate with internal PVDC coating. Reconstitution is performed by pouring the granules into 50 mL to 100 mL water at 20°C to 30°C; the granules wet and disperse within 60 s under gentle stirring. The terminal dosage form is a taste-masked, preservative-free dry suspension because the absence of free water reduces hydrolytic degradation of the polymaltose complex and eliminates the need for benzalkonium chloride or benzoate preservatives.

Granule packaging presents a borderline moisture barrier requirement; aluminium-laminate film with a minimum aluminium foil thickness of 9 µm to 12 µm is selected because thinner foil can develop flex-cracking during form-fill-seal operations, producing pinholes that raise moisture ingress. Seal temperature is controlled at 160°C to 180°C for polyethylene inner layers, with dwell time 0.3 s to 0.6 s and jaw pressure 4 bar to 6 bar; cold seal materials are avoided because the high-density granules can create seal contamination at the jaw face. Stability of the dry granules is monitored for iron release, moisture, and granule friability; granule friability is measured by rotating 10 g of granules in a 100 mL stainless steel vessel with 20 g of 7 mm steel beads for 10 min, and the fraction retained on a 150 µm sieve must exceed 80% w/w. This test is not a compendial method but is adapted from the general principle of USP <1217> for bulk density and powder flow. Retained granule integrity is critical because fractured fines can segregate in the sachet and produce visible dusting that interferes with swallowing and dosing.

If Iron Polymaltose Complex Is Suspended in an Aqueous Vehicle at pH Above 4.5

Oral liquid formulations containing ferric hydroxide polymaltose complex are prepared as suspensions, not solutions, because the complex remains practically insoluble in water and in organic solvents; the suspended particle size is therefore the dominant determinant of sedimentation, resuspendability, and oral grittiness. The aqueous vehicle is buffered with citric acid and sodium citrate to pH 5.0 to 6.0, a range that reduces acid-mediated iron release and limits hydrolysis of the polymaltose shell while remaining compatible with common preservatives. Wetting is achieved by polysorbate 20 at 0.1% to 0.5% w/w, and the suspension is structured with xanthan gum at 0.3% to 0.8% w/w plus microcrystalline cellulose at 0.5% to 1.0% w/w; these rheological additives produce a pseudoplastic yield stress above 0.5 Pa that reduces settled bed formation. Production on a high-shear disperser runs at 3000 rpm to 5000 rpm for 15 min to 30 min, followed by deaeration under vacuum at -60 kPa to -80 kPa to remove entrapped air, which may cause dose non-uniformity. Particle size after dispersing is controlled at D90 not more than 50 µm, measured by laser diffraction; larger fractions can create a sandy mouthfeel and rapid sedimentation. The suspension is filled into amber glass or high-density polyethylene bottles with a fill volume of 100 mL or 200 mL, and the packaged product is tested for preservative efficacy by Ph. Eur. 5.1.3 / USP <51>, elemental impurities by ICH Q3D, and assay by atomic absorption. Storage is specified at 25°C with excursions to 30°C, protected from light; sedimentation volume F after 24 h should be not less than 0.90, with redispersion after 5 inversions. No ethanol is used in the vehicle because alcohol precipitation of the polysaccharide suspending agents would collapse the rheological structure.

Suspension homogeneity at the end of manufacturing is confirmed by stratified sampling from the top, middle, and bottom of the mixing tank after 10 min of gentle recirculation; assay variation between strata must not exceed 2% relative standard deviation before filling. Fill volume is checked by weight using the density of the suspension measured by a pycnometer at 25°C ± 0.5°C; a 100 mL nominal fill is converted to mass using the measured density, and tolerances of ±2% are applied. Shaking and resuspendability are tested in the final package by rotating bottles 5 times and measuring assay at the first and last 10 mL portions; the ratio must be between 0.95 and 1.05. Microbiological quality follows Ph. Eur. 5.1.4 / USP <1111> for oral liquids; the nonsterile product must have total aerobic microbial count not more than 100 CFU/g and total combined yeasts and moulds not more than 10 CFU/g. The suspension is not suitable for high-temperature autoclaving because the xanthan gum structure degrades above 60°C and the polymaltose complex may release iron in acidic sterilising conditions; therefore, preservative protection and controlled raw material bioburden are used.

Injectable Terminal Sterilization Demands a Narrow pH and Oxygen Window

When iron polymaltose complex is manufactured to an injectable grade, the API must meet reduced endotoxin, bioburden, and particulate specifications prior to compounding; published data for this specific injectable configuration are more limited than for oral dosage forms, so formulation development must rely on product-specific stability studies rather than compendial monograph defaults. The complex is dissolved or dispersed in water for injection at an elemental iron concentration of 10 mg/mL to 25 mg/mL, with sodium hydroxide or hydrochloric acid used for pH adjustment to pH 6.0 to 7.5. Isotonicity is achieved with sodium chloride 0.9% w/v or mannitol 4% to 5% w/v; the formulation is blanketed with nitrogen to keep dissolved oxygen below 2 mg/L and to limit Fenton-type redox cycling at the iron surface. The solution is passed through a 0.2 µm filter for bioburden reduction before filling into Type I borosilicate glass vials, which are then stoppered with bromobutyl or chlorobutyl rubber closures and sealed with aluminium caps. Terminal steam sterilisation is conducted at 121°C for 15 min, giving an F0 above 15 min; if a reduced sterilisation cycle at F0 8 to 12 min is selected, pre-filtration bioburden must be below 10 CFU/100 mL and the cycle must be validated according to ISO 17665-1:2006. Sterility is confirmed by USP <71>, bacterial endotoxin by USP <85> with a limit not exceeding 0.50 EU/mg elemental iron, particulate matter by USP <788>, and extractable volume per Ph. Eur. 2.9.17 / USP <1>. The principal incompatibility is oxygen; residual oxygen in the headspace must be below 1% v/v and antioxidant addition is generally avoided because reducing agents can destabilise the polymaltose shell and release ferric ions. The formulation must not be combined with phosphate-buffered diluents, because insoluble ferric phosphate can form after dilution and produce visible particles that fail the light obscuration test.

Scale-up of injectable iron polymaltose complex is constrained by the need to maintain low endotoxin and low particulate load during every transfer. Compounding is conducted in Grade C areas with Grade A local protection at filling, and all product-contact tubing is silicone or PTFE with 0.1 µm pre-filtration before the 0.2 µm sterilising-grade filter. Filter integrity is tested before and after filling by bubble point or forward flow methods per the filter manufacturer, and the maximum filtration volume per 10-inch cartridge is not exceeded to avoid adsorptive loss of the iron complex. The filled vials are inspected by automated light obscuration and manual visual inspection; because the product is dark brown, visible inspection requires back-light dilution or a rotating vial viewer with high-intensity illumination. Any formulation containing reducing sugars is excluded, as the combination of heat sterilisation and residual oxygen can induce Maillard-like browning of the polysaccharide shell. Shipping and storage are maintained at 2°C to 8°C if stability data show aggregate formation at higher temperatures; otherwise, controlled room temperature is justified by stress testing.